Targeting vector applicable to anti-African swine fever virus siRNA (small interfering Ribonucleic Acid) medicine and application of targeting vector
By designing mannose receptor targeting vectors, siRNA drugs are directed into African swine fever virus-infected cells, solving the problem of lack of targeting and toxic side effects of traditional drugs, and achieving efficient and safe viral inhibition effects.
Patent Information
- Application Number
- CN202411209878.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2020-05-25
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art cannot effectively prevent and treat African swine fever virus, and traditional drugs lack targeting and have toxic side effects.
A targeted vector suitable for anti-African swine fever virus was designed, using multivalent sugar chains and adapters to bind mannose receptors to direct siRNA drugs into macrophages or dendritic cells through endocytosis to achieve targeting. effect.
It improves the efficacy of the drug, reduces the toxicity to normal cells, ensures the precise release of siRNA drugs and inhibits the expression of target genes, and achieves the purpose of killing viruses.
Smart Images

Figure CN119074939A_ABST
Abstract
Description
[0001] This application is a divisional application of application number 202010451189.1, application date May 25, 2020, and invention name “A targeting vector suitable for anti-African swine fever virus siRNA drugs and its application”. Technical Field
[0002] The present invention relates to the technical field of drug targeting vectors, and in particular to a targeting vector suitable for anti-African swine fever virus siRNA drugs and applications thereof. Background Art
[0003] A receptor is a macromolecular substance that can recognize and selectively bind to a certain molecule. Receptor-mediated endocytosis is an important way for most animal cells to capture biomacromolecules from extracellular fluid. Most drugs enter cells and change the physiological and biochemical functions of cells to produce effects. Generally, traditional drugs do not have active targeting. While treating diseases, they will have certain toxic side effects and even some adverse reactions. The research and application of drug-targeted carriers can make up for these shortcomings. It can concentrate drugs on targeted cells to maximize the effectiveness of drugs, and at the same time reduce the toxicity of drugs to normal cells. Mannose receptors (MR) are mainly expressed in macrophages and dendritic cells, and are highly expressed in liver, spleen and alveolar macrophages. Macrophages are also an important target for drug delivery. Mannose receptors can recognize sugar chains with mannose at the end.
[0004] African swine fever is an acute, highly contagious disease caused by the African swine fever virus (ASFV) with a very high mortality rate and is usually fatal. African swine fever occurs and is prevalent in many countries, but so far there is no vaccine or drug to prevent or treat the disease. African swine fever virus is a double-stranded DNA virus that mainly infects macrophages, monocytes and dendritic cells. Summary of the invention
[0005] The purpose of the present invention is to provide a targeting vector suitable for anti-African swine fever virus siRNA drugs and its application, so as to solve the shortcomings of the prior art.
[0006] The present invention adopts the following technical solutions:
[0007] The first aspect of the present invention provides a targeting vector suitable for anti-African swine fever virus siRNA drug, comprising a multivalent sugar chain and a linker.
[0008] The multivalent sugar chain is a tetravalent sugar chain, and the sugar unit at the end of the sugar chain is D-mannose, which can be recognized by the mannose receptor; except for the sugar unit, the sugar chain contains 16-20 carbon-carbon / carbon-oxygen / carbon-nitrogen single bonds;
[0009] The linker is used to connect the multivalent sugar chain and the anti-African swine fever virus siRNA drug, and has at least one carboxyl group and one hydroxyl group at the end, which are used to connect with the multivalent sugar chain and the anti-African swine fever virus siRNA drug respectively;
[0010] The tetravalent sugar chain is derived from four carbon chains, each of which contains 2-4 carbon-carbon single bonds and ends with hydroxyl, amino or carboxylic acid groups, one of which contains an amino structure; each carbon chain is connected to the sugar unit through a linking unit composed of an alkyl amide, an alkyl ether or an alkyl amine; the linker is connected to the amino group on the carbon chain through a carboxyl group to form the targeting carrier.
[0011] Furthermore, the siRNA of the anti-African swine fever virus siRNA drug is one of the following double-stranded RNA sequences:
[0012] 1) A double-stranded RNA sequence whose sense strand is SEQ ID NO: 6 in the sequence list and whose antisense strand is SEQ ID NO: 7 in the sequence list;
[0013] 2) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 8 in the sequence listing and whose antisense strand is SEQ ID NO: 9 in the sequence listing;
[0014] 3) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 10 in the sequence listing and whose antisense strand is SEQ ID NO: 11 in the sequence listing;
[0015] 4) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 12 in the sequence listing and whose antisense strand is SEQ ID NO: 13 in the sequence listing;
[0016] 5) A double-stranded RNA sequence whose sense strand is SEQ ID NO: 14 in the sequence listing and whose antisense strand is SEQ ID NO: 15 in the sequence listing.
[0017] Furthermore, the 3′ end of the double-stranded RNA also contains a dTdT structure.
[0018] The second aspect of the present invention provides the use of the above-mentioned targeting vector in loading anti-African swine fever virus siRNA drugs.
[0019] Beneficial effects of the present invention:
[0020] 1. The targeting vector of the present invention is a novel mannose receptor vector, which is combined with a proprietary siRNA drug against African swine fever virus, and can directionally recognize the mannose receptor of macrophages or dendritic cells, and enter the cells through endocytosis, thereby improving the efficacy of the drug and reducing the toxic side effects on other tissues, with strong targeting effect and high safety. In the cell, the siRNA drug can inhibit the expression of the target gene, silencing the target gene, thereby achieving the purpose of killing the virus.
[0021] 2. The sugar chain of the present invention is a multivalent sugar chain, preferably a trivalent sugar chain or a tetravalent sugar chain, and more preferably a tetravalent sugar chain. The affinity of the multivalent sugar chain is stronger than that of the monovalent sugar chain, and it can efficiently target the target area. After entering the cell through endocytosis, the anti-African swine fever virus siRNA drug molecules are accurately released.
[0022] 3. The sugar chain backbone of the present invention contains 13-22 carbon-carbon / carbon-oxygen / carbon-nitrogen single bonds, preferably 16-20 carbon-carbon / carbon-oxygen / carbon-nitrogen single bonds, so that a certain spatial distance is maintained between each sugar unit, and the spatial suitable action distance between each sugar unit and the mannose receptor is ensured, which is conducive to the targeting effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a fluorescent image of mouse macrophages endocytosing sugar molecules.
[0024] Figure 2 This is a diagram of the pEGFP-N1 plasmid structure.
[0025] Figure 3 This is the PCR amplification diagram after O174L gene, H359L gene, MGF 505-7R gene, MGF 360-15R gene, and EP402R gene were transfected into NIH-3T3 cells.
[0026] Figure 4 This is the inhibition rate of O174L-siRNA, H359L-siRNA, MGF505-7R-siRNA, MGF360-15R-siRNA, and EP402R-siRNA on the gene.
[0027] Figure 5 It is the relative expression level of protein by O174L-siRNA, H359L-siRNA, MGF505-7R-siRNA, MGF360-15R-siRNA and EP402R-siRNA. DETAILED DESCRIPTION
[0028] The present invention is further explained below in conjunction with the examples and drawings. The following examples are only used to illustrate the present invention, but are not intended to limit the scope of the present invention.
[0029] A targeting vector suitable for anti-African swine fever virus siRNA drug, comprising a multivalent sugar chain and a linker, and the overall structure is as follows:
[0030] Sugar chain--linker--nucleic acid
[0031] The polyvalent sugar chain is preferably a trivalent sugar chain or a tetravalent sugar chain, more preferably a tetravalent sugar chain. The terminal sugar unit of the sugar chain is D-mannose, which can be recognized by the mannose receptor; except for the sugar unit, the sugar chain preferably contains 13-22 carbon-carbon / carbon-oxygen / carbon-nitrogen single bonds, more preferably 16-20 carbon-carbon / carbon-oxygen / carbon-nitrogen single bonds. The structure is shown below (illustrative but not limited to):
[0032]
[0033] The linker is used to connect the multivalent sugar chain and the anti-African swine fever virus siRNA drug, and has at least one carboxyl group and one hydroxyl group at the end, which are used to connect with the multivalent sugar chain and the anti-African swine fever virus siRNA drug respectively. The structure is shown below (illustrative but not limited to):
[0034]
[0035] The tetravalent sugar chain of the present invention is derived from four carbon chains, each of the four carbon chains used for derivation contains 2-4 carbon-carbon single bonds, and the ends are hydroxyl, amino or carboxylic acid groups, and one of the carbon chains contains an amino structure; each carbon chain is further connected to the sugar unit through a linking unit composed of alkyl amide, alkyl ether or alkyl amine; the linker is connected to the amino group on the carbon chain through the carboxyl group to form the targeting carrier.
[0036] The siRNA of the anti-African swine fever virus siRNA drug is one of the following double-stranded RNA sequences:
[0037] 1) A double-stranded RNA sequence whose sense strand is SEQ ID NO: 6 in the sequence list and whose antisense strand is SEQ ID NO: 7 in the sequence list;
[0038] 2) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 8 in the sequence listing and whose antisense strand is SEQ ID NO: 9 in the sequence listing;
[0039] 3) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 10 in the sequence listing and whose antisense strand is SEQ ID NO: 11 in the sequence listing;
[0040] 4) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 12 in the sequence listing and whose antisense strand is SEQ ID NO: 13 in the sequence listing;
[0041] 5) A double-stranded RNA sequence whose sense strand is SEQ ID NO: 14 in the sequence listing and whose antisense strand is SEQ ID NO: 15 in the sequence listing.
[0042] Preferably, the 3′ end of the double-stranded RNA further contains a dTdT structure to increase the stability of the siRNA.
[0043] Unless otherwise specified, the following experimental methods are conventional methods and the experimental materials can be obtained from commercial companies.
[0044] The following example reaction schemes are as follows:
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053] Example 1: D-mannose acetylation
[0054] At 0°C, 500 ml of anhydrous pyridine (Py) was added to a suspension of 100 g of D-mannose in acetic anhydride (Ac2O) (400 ml), nitrogen was passed through, and the mixture was stirred for 15 minutes; then 5 g of 4-dimethylaminopyridine (DMAP) and 100 ml of triethylamine (Et3N) were added to the reaction mixture, and the mixture was stirred overnight. After the reaction was complete (the reaction was monitored by thin layer chromatography), the precipitated solid was collected, washed twice with toluene and water respectively, and dried in vacuo to obtain 160 g of fully acetylated D-mannose.
[0055] Example 2: Protecting Glycosyl-Linked Carboxylates
[0056] 120 g of peracetyl-D-mannose was added to 1 liter of anhydrous dichloroethane (DCE) under nitrogen protection, and then 60 ml of trimethylsilyl trifluoromethanesulfonate (TMSOTf) was slowly added dropwise, and stirred for 16 hours at 25-30° C. The reactants were then transferred to 3 liters of ice-water suspension containing 15 wt% sodium bicarbonate and stirred for 1 hour, then allowed to stand, the organic layer was collected, the aqueous layer was extracted twice with dichloromethane (DCM), the organic layers were combined and dried over anhydrous magnesium sulfate, filtered and concentrated to dryness, and 105 g of the product was directly used in the next step.
[0057] 105 g of the above product and 105 g of benzyl 4-hydroxybutyrate were dissolved in 600 ml of anhydrous dichloroethane (DCE), 80 g of molecular sieves were added and stirred for 20 minutes, then 14 ml of trimethylsilyl trifluoromethanesulfonate (TMSOTf) was added and stirred for 16 hours at 25-30° C. The reactant was poured into 1.5 liters of sodium bicarbonate solution (15wt%) mixed with ice water, stirred for 1 hour, allowed to stand, the organic layer was collected, the aqueous layer was extracted twice with dichloromethane (DCM), the organic layers were combined and dried over anhydrous magnesium sulfate, filtered and concentrated to obtain a crude product, which was purified by column chromatography to obtain 147 g of a light yellow oily liquid.
[0058] Example 3: Debenzylation of Carboxylic Acid Ester
[0059] 100 g of the benzyl ester of Example 2 was dissolved in 1 liter of methanol / tetrahydrofuran (THF) mixed solvent (methanol:tetrahydrofuran volume ratio = 1:1), nitrogen was passed through to remove a small amount of air in the solution, and 10 g of 10 wt% palladium carbon (Pd / C) was added under nitrogen protection. Then the nitrogen was replaced with hydrogen three times, and stirred at 25-30°C overnight under hydrogen. The reactant was filtered through diatomaceous earth and washed with methanol, and the filtrate was collected and concentrated to dryness to obtain 87 g of the product.
[0060] Example 4: Aminoamide chain synthesis
[0061] 15 g of Boc-protected aminotetracarboxylic acid compound and 47 g of N-Fmoc-1,4-diaminobutane were dissolved in 250 ml of dimethylformamide (DMF), 25 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl), 18 g of 1-hydroxybenzotriazole (HOBt) and 35 ml of N-methylmorpholine (NMM) were added, and the reactants were stirred at 25°C for 16 hours. After the reaction was complete (central control was performed using thin layer chromatography), the reactants were poured into 1.5 liters of ice water and extracted twice with dichloromethane (DCM), the organic layers were combined and washed with 1M dilute hydrochloric acid solution and saturated sodium chloride solution, then dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product obtained after concentration was purified by column chromatography to obtain 32 g of off-white solid, mass spectrum: C 103 H 127N9O 18 Theoretical molecular weight, 1778.93, detected molecular weight (M+Na), 1801.6.
[0062] Example 5: Synthesis of linkers
[0063] 11 g of DMTr protected trans-4-hydroxyprolinol and 6.83 g of 5-(6-methoxy-6-oxohexanamido)pentanoic acid were dissolved in 200 ml of dimethylformamide (DMF), followed by the addition of 12 g of o-benzotriazole-n,n,n',n'-tetramethyluronium hexafluorophosphate (HBTU) and 14 ml of N,N-diisopropylethylamine (DIEA), and stirred overnight. The reactants were poured into a 1.2 liter ice-water mixture and extracted with dichloromethane (DCM). The organic layer was collected, washed with saturated sodium bicarbonate solution, water and saturated sodium chloride solution, respectively, and dried over anhydrous sodium sulfate. After the organic layer was dried in vacuo, the concentrate was purified by column elution with 5 v / v% methanol / dichloromethane (DCM) to obtain 15.31 g of white solid.
[0064] Example 6: Preparation of linkers
[0065] 12.75 g of the product of Example 5 was dissolved in 150 ml of a mixed solution of tetrahydrofuran (THF) / water (volume ratio = 2:1), followed by the addition of 5.7 g of lithium hydroxide and stirring overnight. After the reaction was complete (central control by thin layer chromatography), the pH was adjusted to 5 with a 1 mol / L acetic acid solution. After concentration, the aqueous layer was extracted with dichloromethane (DCM). The organic layer was collected, and an excess of triethanolamine (TEA) was added and filtered to obtain 12.3 g of TEA salt.
[0066] Example 7: Removal of Boc group from aminoamide chain
[0067] 16 g of the product of Example 4 was dissolved in 100 ml of 2M HCl in ethyl acetate (EA) and stirred at 25° C. for 3 hours. After the reaction was complete (central control by thin layer chromatography), HCl and ethyl acetate were distilled off under reduced pressure to obtain a crude product, which was dissolved in ethyl acetate and distilled off under reduced pressure again. The obtained product was used for the next condensation step.
[0068] Example 8: Aminoamide chain and linker condensation
[0069] 9.7 grams of the product of Example 7 and 6.2 grams of o-benzotriazole-n,n,n',n'-tetramethyluronium hexafluorophosphate (HBTU) were dissolved in 250 ml of dimethylformamide (DMF), followed by addition of 8 ml of N,N-diisopropylethylamine (DIEA) and stirring for 3-4 minutes. Subsequently, 30 grams of the product of Example 6 were dissolved in 250 ml of dimethylformamide (DMF) and added to the reaction solution. After stirring overnight at room temperature, the organic layer was evaporated under reduced pressure and the aqueous layer was extracted with dichloromethane (DCM). The organic layer was collected, washed with saturated sodium bicarbonate solution and water respectively, dried over anhydrous sodium sulfate and concentrated. The concentrate was purified by column elution with a 5-20 v / v% methanol / dichloromethane (DCM) gradient to obtain 24.8 g of a white solid, mass spectrum: C 135 H 163 N 11 O 23 , theoretical molecular weight, 2307.20, detected molecular weight (M+Na), 2329.9.
[0070] Example 9: Removal of Fmoc group from condensation product
[0071] 14 g of the product of Example 8 was dissolved in a dimethylformamide (DMF) solution containing 20 wt% diethylamine (DEA) and stirred at 25° C. for 2 hours. After the reaction was complete (central control by thin layer chromatography), the solvent was removed at no more than 30° C., and then methyl tert-butyl ether was added to the concentrated product, stirred, filtered and washed, and vacuum dried to obtain 7.8 g of the product.
[0072] Example 10: Multivalent chain-linked sugar groups
[0073] 7 g of the product of Example 9 and 6.4 g of the product of Example 3 were dissolved in 100 ml of dimethylformamide (DMF), and 4 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl), 3 g of 1-hydroxybenzotriazole (HOBt) and 5.8 ml of N, N-diisopropylethylamine (DIPEA) were added. The reactants were stirred at 25°C for 16 hours. After the reaction was complete (central control was performed by thin layer chromatography), the reactants were poured into 500 ml of ice water and extracted twice with ethyl acetate. The combined organic layers were washed with 1M dilute hydrochloric acid solution and saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product obtained after concentration was purified by column chromatography to obtain 12.4 g of off-white solid, mass spectrum: C 147 H 219 N 11 O 59 , theoretical molecular weight, 3083.45, detected molecular weight (M+Na), 3106.1.
[0074] Example 11: Hydroxyl Protecting Group
[0075] 0.2 g of N-benzyloxycarbonylglycine was dissolved in 20 ml of dichloromethane (DCM), 0.24 g of dicyclohexylcarbodiimide (DCC) and 0.01 g of 4-dimethylaminopyridine (DMAP) were added, and 3 g of the product of Example 10 were stirred at 25°C for 20 hours. After the reaction was complete (central control was performed using thin layer chromatography). After the reaction was completed, the reactant was poured into 50 ml of ice water, filtered to remove the white solid, the aqueous layer was extracted twice with dichloromethane (DCM), the combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product obtained after concentration was purified by column chromatography to obtain 3.02 g of off-white solid.
[0076] Example 12: Deamino Protecting Group
[0077] 3.02 g of the product of Example 11 was dissolved in 20 ml of ethanol, 0.15 g of palladium on carbon (Pd / C) was added, and the mixture was poured into a high pressure reactor. After nitrogen replacement 3 times, hydrogen was introduced and the reaction was carried out at 0.3 MPa for 10 hours. After the reaction was complete (central control was performed using thin layer chromatography), the palladium on carbon (Pd / C) was removed by filtration after the reaction was completed, and the filtrate was evaporated to dryness and directly used in the next step.
[0078] Example 13: Linking Fluorescein
[0079] The product of Example 12 was dissolved in 20 ml of ethanol, and 1 ml of N,N-dimethylformamide (DMF) was added. 0.39 g of fluorescein isothiocyanate was added, and the pH was adjusted to 5 with triethylamine (Et3N). The mixture was stirred overnight at 0°C, and the ethanol was evaporated under reduced pressure. 20 ml of ice water was added while cooling. After stirring for 30 minutes, the mixture was filtered and dried to obtain 3.2 g of a white solid.
[0080] Example 14: Deacetylation
[0081] 3.2 g of the product of Example 13 was dissolved in 20 ml of ethanol, 0.2 g of water and 0.2 g of triethylamine (Et3N) were added, and the mixture was stirred at 25-30°C for 36 hours. The ethanol was evaporated under reduced pressure, and the mixture was washed with 10 ml of acetonitrile by stirring, and filtered and dried to obtain 2.4 g of a red solid.
[0082] Example 15: Endocytosis of Glycosyl Molecules
[0083] Dissolve 0.45 grams of the product of Example 14 in ultrapure water to prepare a solution with a concentration of 150ug / mL. Under a sterile environment, culture mouse macrophages on a cell sheet, add 100ul of the above solution to the cell sheet containing mouse macrophages, keep warm at 37 degrees for 30 minutes, then wash the mouse macrophages twice with PBS buffer (0.01M, PH7.4), add 100uL 4wt% paraformaldehyde to fix the cells for 10 minutes, and then add an appropriate amount of 50v / v% glycerol to seal the slide. Place the slide under an inverted fluorescence microscope and observe, and it is found that the mouse macrophages have green fluorescence (such as Figure 1 This indicates that the new mannose carrier binds to the receptor and successfully enters the macrophage.
[0084] Example 16: Design and synthesis of siRNAs for African swine fever virus O174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, and EP402R gene
[0085] Referring to the siRNA design principles, the ideal siRNA sequence was searched 50-100 nt downstream of the start codon AUG of the target mRNA, and the 21 nt sequence adjacent to its 3′ end was used as the candidate target. The GC content was controlled between 30% and 52%, and more than 4 consecutive A or T were avoided. A group of siRNAs were designed and synthesized according to the corresponding target sites, and compared with the pig genome sequence using the Blast function to ensure that there was no homology with pig genes. Finally, the target sequence of MGF505-7R was selected to correspond to the 1258-1276 sequence of the MGF505-7R gene, the target sequence of MGF360-15R corresponded to the 541-559 sequence of the MGF360-15R gene, the target sequence of EP402R corresponded to the 871-889 sequence of the EP402R gene, the target sequence of H359L corresponded to the 952-970 sequence of the H359L gene, and the target sequence of O174L corresponded to the 284-302 sequence of the O174L gene, among which the number of consecutive matching bases for non-target genes did not exceed 15 base pairs.
[0086] Its sequence is shown in the following table (the uracil in the following sequence RNA is represented by "U", while it is represented by "t" in the sequence table):
[0087]
[0088]
[0089] Example 17: In vitro construction of African swine fever virus O174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, EP402R gene
[0090] Taking African swine fever virus O174L gene (sequence number: 41901960), H359L gene (sequence number: 41901976), MGF505-7R gene (sequence number: 41902799), MGF360-15R gene (sequence number: 41902808), and EP402R gene (sequence number: 41901921) as target sequences, Nanjing GenScript Biotechnology Co., Ltd. was commissioned to synthesize oligonucleotide fragments in a virus-free system. The ends of the fragments were complementary to each other and then extended to each other through the PCR process. Finally, they were assembled into the complete RO174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, and EP402R gene, respectively. The assembled RO174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, and EP402R gene were cloned into the plasmid pEGFP-N1 plasmid ( Figure 2 As shown), eukaryotic expression plasmids pEGFP-RO174L, pEGFP-H359L, pEGFP-MGF505-7R, pEGFP-MGF360-15R, and pEGFP-EP402R were obtained. After sequencing analysis, the obtained O174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, and EP402R gene sequences were consistent with the O174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, and EP402R gene sequences of African swine fever virus, which was completely in line with the expected design.
[0091] Example 18: Cell culture and in vitro constructed viral gene transfection
[0092] NIH-3T3 cells were cultured in a culture flask containing 10% (v / v) fetal bovine serum DMEM (high glucose) medium and placed in a 37°C sterile CO2 cell culture incubator. Approximately 1.2×10 NIH-3T3 cells of uniform size and good condition were cultured. 6Divide into 6-well plates and distribute them evenly. After 24 hours, the constructed pEGFP-O174L, pEGFP-H359L, pEGFP-MGF505-7R, pEGFP-MGF360-15R, and pEGFP-EP402R plasmids were transfected according to the SuperFect Transfection instructions. After 6 hours of transfection, the cell medium was changed 1-2 times. After 48 hours, the cell supernatant was harvested and centrifuged at 45,000 rpm and 4°C for 2 hours. The cells at the bottom of the tube were resuspended with a small amount of DMEM high-glucose medium. The total DNA of the transfected cells was extracted, and the results of PCR analysis showed that the O174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, and EP402R gene fragments were successfully amplified (such as Figure 3 As shown), it shows that the O174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, and EP402R gene constructed in vitro can correctly transcribe the target gene in the host cell.
[0093] Example 19: Transfection of siRNA
[0094] Approximately 1.2×10 NIH-3T3 cells infected with pseudovirus containing O174L gene, H359L gene, MGF505-7R gene, MGF360-15R gene, and EP402R gene were cultured. 4 Divide into 24-well plates and transfect after 24 hours. Transfection is carried out according to the instructions of lipofectamine RNAiMAX transfection. The final concentration of siRNA in each well of the large well is 50nM, and lipofectamine RNAiMAX is added 1Ul. Remove the cell supernatant 6 hours after transfection, add fresh DMEM high-glucose medium and culture for 24 hours, then divide the cells into 96-well plates and transfect for 48 hours.
[0095] Example 20: Real-time fluorescence quantitative PCR detection of siRNA inhibitory effect on genes
[0096] The cells of Example 19 were collected respectively, and total DNA was extracted with trizol reagent. The inhibitory effect of siRNA on the gene was observed by real-time fluorescence quantitative PCR. The real-time fluorescence quantitative PCR used a fluorescence quantitative PCR kit (QIAGEN) and GAPDH was used as the internal reference gene. The results showed (as shown in Figure 4As shown), compared with the negative control group, the inhibition rate of O174L-siRNA on O174L gene was 75.3%; the inhibition rate of H359L-siRNA on H359L gene was 82.6%; the inhibition rate of MGF505-7R-siRNA on H359L gene was 81.4%; the inhibition rate of MGF360-15R-siRNA on MGF360-15R gene was 87.3%; the inhibition rate of EP402R-siRNA on EP402R gene was 79.7%.
[0097] Example 21: Detection of the expression of RDRP and S protein in VeroE6 cells by flow cytometry
[0098] 72 hours after siRNA transfection, NIH-3T3 cells in each well were collected, digested with trypsin, added with 5 ml DMEM high-glucose medium and repeatedly blown, centrifuged at 1000 rpm for 5 minutes, washed twice with PBS buffer (0.01M, pH 7.4) and resuspended in PBS. The average fluorescence intensity of cells in each well and the ratio of fluorescence-positive cells were detected by flow cytometry at a laser wavelength of 488 nm, and the total fluorescence intensity of cells in each well was calculated. The results are shown (as shown in Figure 5 As shown), compared with the negative control group, the inhibition rate of O174L-siRNA on DNA polymerase was 74.8%; the inhibition rate of H359L-siRNA on RNA polymerase was 80.5%; the inhibition rate of MGF505-7R-siRNA on MGF505-7R regulatory protein was 79.3%; the inhibition rate of MGF360-15R-siRNA on MGF 360-15R regulatory protein was 86.7%; the inhibition rate of EP402R-siRNA on EP402R regulatory protein was 77.9%.
[0099] Example 22: Acetyl Protecting Group on Hydroxyl Group
[0100] 7.5 g of the product of Example 10 was dissolved in 50 ml of tetrahydrofuran (THF), 0.3 g of acetic anhydride was added, and a solution of 0.25 g of pyridine (Py) in tetrahydrofuran (THF) (10 ml) was added dropwise under an ice-water bath. The addition was completed in half an hour, and the temperature was controlled at 0-5°C. The reaction was kept at 25-30°C overnight to gradually precipitate a solid. After the reaction was complete (central control was performed by thin layer chromatography), the mixture was filtered, and the filtrate on the solid was rinsed with water until it was neutral. The solid was purified by column chromatography to obtain 6.5 g of an off-white solid.
[0101] Example 23: Coupling Nucleic Acids
[0102] 50 mg of the product of Example 22 was dissolved in 5 ml of water, and a buffer solution (50 mM MES, pH 6.0, 0.01% Triton X-100) and 30 mg of MGF 360-15R-siRNA nucleic acid fragment were added. 25 mg of pyridine (Py) and 2,4,6-triisopropylbenzenesulfonyl chloride were added, and the mixture was placed on a shaker and shaken overnight. The liquid was separated by desalting high-throughput liquid chromatography-mass spectrometry to obtain 2.5 ml of liquid containing the product.
[0103] Example 24: Deacetylation
[0104] 2.5 ml of the liquid of Example 23 were added with 5 ml of water and 0.1 g of triethylamine (Et3N). After stirring at 25-30°C for 36 hours, the target product was separated by preparative liquid separation and freeze-dried to obtain 22.5 mg of solid.
Claims
1. A targeting vector suitable for anti-African swine fever virus siRNA drug, characterized in that: including multivalent sugar chains and linkers, The multivalent sugar chain is a tetravalent sugar chain, and the sugar unit at the end of the sugar chain is D-mannose, which can be recognized by the mannose receptor; except for the sugar unit, the sugar chain contains 16-20 carbon-carbon / carbon-oxygen / carbon-nitrogen single bonds; The linker is used to connect the multivalent sugar chain and the anti-African swine fever virus siRNA drug, and has at least one carboxyl group and one hydroxyl group at the end, which are used to connect with the multivalent sugar chain and the anti-African swine fever virus siRNA drug respectively; The tetravalent sugar chain is derived from four carbon chains, each of which contains 2-4 carbon-carbon single bonds and ends with hydroxyl, amino or carboxylic acid groups, one of which contains an amino structure; each carbon chain is connected to the sugar unit through a linking unit composed of an alkyl amide, an alkyl ether or an alkyl amine; the linker is connected to the amino group on the carbon chain through a carboxyl group to form the targeting carrier.
2. The targeting vector suitable for anti-African swine fever virus siRNA drug according to claim 1, characterized in that: The siRNA of the anti-African swine fever virus siRNA drug is one of the following double-stranded RNA sequences: 1) A double-stranded RNA sequence whose sense strand is SEQ ID NO: 6 in the sequence list and whose antisense strand is SEQ ID NO: 7 in the sequence list; 2) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 8 in the sequence listing and whose antisense strand is SEQ ID NO: 9 in the sequence listing; 3) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 10 in the sequence listing and whose antisense strand is SEQ ID NO: 11 in the sequence listing; 4) a double-stranded RNA sequence whose sense strand is SEQ ID NO: 12 in the sequence listing and whose antisense strand is SEQ ID NO: 13 in the sequence listing; 5) A double-stranded RNA sequence whose sense strand is SEQ ID NO: 14 in the sequence listing and whose antisense strand is SEQ ID NO: 15 in the sequence listing.
3. The targeting vector suitable for anti-African swine fever virus siRNA drug according to claim 2, characterized in that: The 3′ end of the double-stranded RNA also contains a dTdT structure.
4. Use of the targeting vector described in any one of claims 1 to 3 in loading anti-African swine fever virus siRNA drugs.
